Infection

Drinking apple cider vinegar may help with weight loss but its health benefits are overstated

Retrieved on: 
星期三, 四月 10, 2024
Well, Research, Disease, Overweight, Health, Glucose, Diarrhea, Myocardial infarction, Apple, Cell, Serum, Infection, Appetite, Vegetable, Incidence, Acetic acid, Risk, Physiology, Lipid, Insulin, Diabetes, Weight loss, Internet, Stroke, Blood, Mortality, Cancer, Systematic review, Breakfast, Diet, Cholesterol, Vomiting, Drinking water, Dietary supplement

One day, she explained that she adds apple cider vinegar to improve my health.

Key Points: 
  • One day, she explained that she adds apple cider vinegar to improve my health.
  • Apple cider vinegar is a natural product made of fermented apple juice that has gone sour.
  • I decided to turn medical sleuth and investigate whether apple cider vinegar is as good for health as it sounds.

Claim: disinfectant properties

  • But does apple cider vinegar’s decontaminant qualities translate to the human gut?
  • Our stomachs produce acid, which acts as a natural barrier to infection, so how can adding more acid help?

Claim: weight loss and management of type 2 diabetes

  • There are plenty of anecdotal claims that apple cider vinegar can aid weight loss, supported by limited evidence from several small studies.
  • Apple cider vinegar is thought to cause weight loss through its effect on delay of gastric emptying.
  • Reduced calorific intake will lead to weight loss – but how are the metabolic effects on blood glucose and lipids mediated?
  • In type 2 diabetes there is a reduction in sensitivity to insulin which in turn leads to a reduced uptake of glucose by cells.

Claim: reduces risk of heart disease

  • Raised blood lipids are a risk factor for cardiovascular diseases such as myocardial infarction and stroke.
  • Well, I’m afraid there’s no scientific evidence that vinegar consumption of any kind reduces cardiovascular morbidity and mortality in those with or without diabetes.

Claim: cancer treatment and prevention

  • One of the more outrageous claims of benefits of daily apple cider vinegar consumption is that it may prevent or treat cancer.
  • A frequently quoted case-control study from China found that an increased consumption of vinegar was associated with a reduced incidence of oesophageal cancer.


Stephen Hughes does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Pubic hair: beyond brazilians, more than manscaping

Retrieved on: 
星期三, 四月 10, 2024
Research, Health, Urinary tract infection, Gas, Vibration, Hair loss, Friction, Pressure, Facial expression, Science, Risk, Perspiration, Observation, Partner (business rank), Bacteria, Pheromone, Human, Woman, Body image, Sensation, Urine, Infection, Skin, Eyebrow, Scalp, Gland, Ammonia, Urea, Animal, Emotion

So, what about pubic hair?

Key Points: 
  • So, what about pubic hair?
  • Let’s talk about sex
    Much of the effort that goes into shaping or removing pubic hair also shapes and defines sexual identities.
  • While the properties of pheromones are not as well established in humans, there’s speculation that pubic hair plays a significant role.
  • Pubic hair grooming has been associated with an increased risk of genital infections but this has also been refuted.

Infections after surgery are more likely due to bacteria already on your skin than from microbes in the hospital − new research

Retrieved on: 
星期三, 四月 10, 2024
Research, Bacteria, Pneumonia, Science Translational Medicine, CSI, Fungal infection, Instrument, Infection, Patient, Harborview Medical Center, Accreditation, Hospital, Diarrhea, University, Death, Escherichia coli, Staphylococcus aureus, Bloodstream infections, Neurosurgery, Woman, Quality, Agency, Skin, Microbiology, Pharmacy, Spine, Nose, Nursing care plan, Elective surgery, Neck, Dentistry

Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.

Key Points: 
  • Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.
  • We show that many surgical site infections after spinal surgery are caused by microbes that are already on the patient’s skin.

Surgical infections are a persistent problem

  • Among the different types of heath care-associated infections, surgical site infections stand out as particularly problematic.
  • A 2013 study found that surgical site infections contribute the most to the annual costs of hospital-acquired infections, totaling over 33% of the US$9.8 billion spent annually.
  • Still, surgical site infections occur following about 1 in 30 procedures, typically with no explanation.
  • While rates of many other medical complications have shown steady improvement over time, data from the Agency for Healthcare Research and Quality and the Centers for Disease Control and Prevention show that the problem of surgical site infection is not getting better.

BYOB (Bring your own bacteria)

  • Prior studies on surgical site infection have been limited to a single species of bacteria and used older genetic analysis methods.
  • But new technologies have opened the door to studying all types of bacteria and testing their antibiotic resistance genes simultaneously.
  • Over a one-year period, we sampled the bacteria living in the nose, skin and stool of over 200 patients before surgery.
  • In fact, 86% of the bacteria causing infections after spine surgery were genetically matched to bacteria a patient carried before surgery.
  • That number is remarkably close to estimates from earlier studies using older genetic techniques focused on Staphylococcus aureus.
  • They likely acquired these antibiotic-resistant microbes through prior antibiotic exposure, consumer products or routine community contact.

Preventing surgical infections

  • At face value, our results may seem intuitive – surgical wound infections come from bacteria that hang out around that part of the body.
  • If the most likely source of surgical infection – the patient’s microbiome – is known in advance, this presents medical teams with an opportunity to protect against it prior to a scheduled procedure.
  • The fact that most infections don’t actually start with sources in the hospital is probably a testament to the efficacy of these protocols.


Dustin Long receives funding from the National Institutes of Health. Dr Bryson-Cahn receives funding from the Gordon and Berry Moore Foundation and is the co-medical director for Alaska Airlines.

EQS-News: Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study

Retrieved on: 
星期三, 四月 10, 2024
Multiple myeloma, Bone marrow, Cohort, Infection, Incidence, BCMA, Patient, Plasma cell, Mortality, B cell, Spacecraft, AACR, Annual report, Antibody, The Annual Report, Safety, Pharmacokinetics, HPHA, FDA, ATAC, Food, Pharmaceutical industry

Multiple myeloma is a type of blood cancer that develops from plasma cells in the bone marrow and can affect more than one part of the body.

Key Points: 
  • Multiple myeloma is a type of blood cancer that develops from plasma cells in the bone marrow and can affect more than one part of the body.
  • Plasma cells are a type of blood cell that makes antibodies to fight infection, created by bone marrow.
  • Heidelberg Pharma’s Phase I/IIa clinical study is an ongoing, non-randomised, open label study which is actively enrolling patients with relapsed or refractory multiple myeloma or other plasma cell disorders expressing BCMA.
  • Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, said: “Our proprietary ATAC candidate HDP-101 is showing exciting potential for treating multiple myeloma.

EQS-News: TVM CAPITAL LIFE SCIENCE TO PARTICIPATE IN LSI USA ’24 EMERGING MEDTECH SUMMIT 2024

Retrieved on: 
星期三, 四月 10, 2024
Radiation, Thrombosis, Partner (business rank), Infection, Intelligence, TVM, Risk, General partnership, Patient, Eye injury, Standard of care, AI, Workflow, Investment, LSI, Phlebitis, Eli Lilly and Company, Vector, Therapy, FDA, Physician, Health, PFC, Medical imaging

Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.

Key Points: 
  • Munich, Germany and Montreal, Quebec, Canada (March 13, 2024) – TVM Capital Life Science (“TVM”), a leading international venture capital firm focused on investments in life sciences innovation, today announced that the Company will participate in the sixth annual LSI USA ’24 Emerging Medtech Summit 2024, which brings together leading innovators, active investors and committed strategics from the medtech industry to partner and build next-generation healthcare technologies.
  • The conference will take place March 18-22, 2024, in Dana Point, California, USA.
  • "Medtech innovation continues to be at the forefront of healthcare advancement, driving transformative changes in patient care, operational efficiency and cost reduction.
  • As part of our commercial-stage medical technologies investment strategy, TVM seeks breakthrough solutions that align with emerging trends and could redefine the standard of care.

EQS-News: AdrenoMed Receives FDA Fast Track Designation for Enibarcimab for Treatment of Septic Shock

Retrieved on: 
星期三, 四月 10, 2024
Sepsis, Communication, Patient, Public, Fast Track, Adrenomedullin, Biomarker, Accelerated approval (FDA), Mortality, Septic shock, Death, DPP3, Septic, Medicine, Priority review, Organ dysfunction, Intensive care medicine, CMO, Collection, FDA, Infection, RCI, Food, Pharmaceutical industry

AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.

Key Points: 
  • AdrenoMed is now preparing a confirmatory Phase IIb/III clinical trial to confirm the reduced septic shock mortality under enibarcimab treatment employing a precision medicine approach.
  • AdrenoMed’s CEO Dr. Richard Jones commented: “We are very pleased that enibarcimab has received Fast Track designation from the FDA, recognizing its potential as an innovative biomarker-guided treatment against septic shock to fill the unmet medical need in this very serious condition with a high death toll.
  • With a mortality rate of 20-30% for sepsis [1] and 30%-50% for septic shock in developed countries, [2] sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths worldwide.
  • Dr. Stephan Witte, CMO of AdrenoMed, said: “We are very confident that the use of enibarcimab in combination with two biomarkers, Adrenomedullin (bio-ADM) and circulating dipeptidyl peptidase 3 (cDPP3), holds the promise to become the first effective targeted treatment against septic shock.

EQS-News: G.ST Antivirals reports start of Phase II trial and announces appointment of Ronald Bruce Turner as new Chief Medical Officer

Retrieved on: 
星期三, 四月 10, 2024
JAMA, Recreational vehicle, Metabolism, CHDR, Entrepreneurship, Dean (education), Viral, Reproduction, University, Head, Volunteering, MD, Urinary tract infection, Infection, Medical school, Clinical trial, Pharmacokinetics, Southern Illinois University, Division, Virus, CMO, University School, Glycolysis, Pharmaceutical industry

An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.

Key Points: 
  • An expert in the clinical research of respiratory viruses, Dr. Turner will oversee the Company’s current clinical trial and drive further clinical development.
  • This study aims to assess the effectiveness of 2-DG in preventing illness from rhinoviruses, reducing infection rates, and easing symptom severity.
  • A total of 128 volunteers will participate, receiving up to four daily intranasal doses of either 2-DG or a placebo.
  • 2-DG is a unique and intriguing therapeutic approach to treating viral infections by blocking the virus’ nutrient access,” commented Ronald Bruce Turner, MD, CMO of G.ST Antivirals.

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
星期二, 四月 9, 2024
Antimalarial medication, Polyene, Fungal infection, Candidiasis, Congress, Biotechnology, Azole, Candida auris, Patient, Mouse, Infection, University, NOS, Echinocandin, University of Texas System, Fluconazole, ECCMID, European, Candida glabrata, Pharmaceutical industry

These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.

Key Points: 
  • These presentations at ECCMID 2024 continue to build upon SCY-247’s positive preclinical data illustrating its unique attributes in the fight against difficult-to-treat fungal infections.
  • Candida auris is an emerging fungal pathogen associated with nosocomial infections and considered a serious global health threat.
  • The work here utilized the National Institute of Allergy and Infectious Diseases’ (NIAID’s) suite of preclinical services for in vivo testing (Contract Nos.
  • SCY-247, a novel second-generation IV/oral triterpenoid antifungal, demonstrates in vitro activity against fungal pathogens, including azole-resistant strains of Candida and Aspergillus

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Retrieved on: 
星期二, 四月 9, 2024
Colistin, Beta-lactam, Education, Development, Partnership, Patient, HHS, Gram-negative bacteria, Escherichia coli, World Health Organization, Infection, USD, Administration, Antibiotic, BMBF, Pharmaceutical industry

The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.

Key Points: 
  • The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis.
  • Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project achieves certain milestones.
  • The program comprises antibiotics targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • The molecules belong to one of the very few novel classes of antibiotics in development.

Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024

Retrieved on: 
星期一, 四月 8, 2024
AP, Infection, HIV, Nature Biotechnology, Epitope, Cancer, SARS-CoV-2, Gritstone bio, HLA, AACR, Immunity, EDGE, Poster, Vaccine

EMERYVILLE, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today presented an update on its T cell epitope discovery platform, EDGE, at the 2024 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 (Nature Biotechnology). It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.

Key Points: 
  • The presentation details improvements Gritstone has made in prediction of peptide presentation by HLA Class I, associated with CD8+ T cells, since the publication of the initial results in 2018 ( Nature Biotechnology ).
  • It also reviews how Gritstone has expanded EDGE’s application to predict peptide presentation by HLA Class II.
  • “Identifying which of the hundreds of tumor mutations are most likely to serve as neoantigens, key targets of tumor-specific T cells, is critical to the development of effective neoantigen-directed vaccines,” said Andrew Allen, M.D., Ph.D., Co-founder, President, and Chief Executive Officer of Gritstone bio.
  • The improvements we are making to EDGE, leveraging advances in protein large language models and in-house immunopeptidomics, have positioned EDGE as a leading HLA/peptide predictive platform in the neoantigen cancer vaccine field.